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A number of studies have addressed the prevalence and
signiﬁcance of cardiovascular disease (CVD) worldwide.
According to the Global Burden of Disease Study 2010,
age-standardized death rates for CVD decreased by app-
roximately 20% in the last 2 decades, but coronary heart
disease (CHD) and stroke constitute the 2 leading causes of
death in the world due to respective 35% and 26% increases
in crude mortality (Fig. 1) (1). Furthermore, when com-
bining years of life lost and years lived with disability, CHD
and stroke rank ﬁrst and third, respectively (2). Amongst
risk factors, arterial hypertension was identiﬁed as the main
source of combined mortality and morbidity, accounting for
7% of global disability-adjusted life years. The respective
values for obesity, hyperglycemia, and hypercholesterolemia,
were 3.8%, 3.6%, and 1.6% (3). Physical inactivity was
estimated to account for 6% of the burden of CHD
worldwide, with a larger relative impact in higher-income
regions (4). The concept of atherothrombosis as a modern
ailment was challenged by imaging studies in ancient
mummies from various geographic areas that demonstrated
frequent multivascular calciﬁcation (5).
The early development of atherosclerosis in life was revis-
ited in a contemporary autopsy series of 3,832 U.S. soldiers
(mean age 26 years, 98% men). The prevalence of coronary
atherosclerosis was 8.5%, and it was associated with dyslipi-
demia, hypertension, and obesity (6). According to a meta-
analysis of 18 cohorts mostly from the United States and
>250,000 individuals with 40 to 80 years of age, the lifetime
risk of death from CVD is approximately 30% (7). This
hazard is modulated by the number of conventional risk
factors, but <5% of participants had an optimal risk proﬁle
(Table 1) (7,8). Furthermore, when not only mortality but all
events are accounted for, lifetime risk surpasses 50% for both
sexes across all age strata (8). When 7 metrics of ideal
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prevalence of ideal health was 1.2% in the National Health
and Nutrition Examination Survey (NHANES) 2005 to
2010 (9). Different NHANES cycles from 1988 to 2008
indicated that smoking, hypercholesterolemia, and hyperten-
sion prevalence declined; obesity and dysglycemia increased;
and physical activity levels and diet quality changed minimally
in the United States. Obesity and impaired fasting glucose/
diabetes mellitus were projected to increase by 10% and 19%,
respectively, by 2020 (Fig. 2) (10). Also according to
NHANES data, the current prevalence of hypertension is
approximately 30% amongst American adults: rates of ma-
nagement and control (deﬁned as <140/90 mm Hg) are 72%
and 47%, respectively, with no advances since 2007 (11). The
prevalence of obesity (body mass index 30 kg/m2) is 36%,
similarly without improvements in recent years (12). Al-
though smoking has decreased, tobacco use in women now
triples their relative risk of death from CVD (similar to their
male counterparts), due to initiation at an earlier age (13).Mechanisms of Disease
Systemic inﬂammation. Although experimental studies
have proven a causative role of monocytes in atherogenesis,
epidemiological studies have produced controversial results.
In 951 patients undergoing catheterization, 3 subsets of
monocytes were evaluated according to their surface
expression of the lipopolysaccharide receptor (CD14) and
the low-afﬁnity Fcg-III receptor (CD16): classic
(CD14þþCD16), intermediate (CD14þþCD16þ), and
nonclassical monocytes (CD14þCD16þþ). After a mean
follow-up of 2.6 years, nonclassical CD14þþCD16þ were
the only subset independently related to cardiovascular
events (hazard ratio: 3.019, p ¼ 0.009) (Fig. 3) and might
constitute a target cell population for new therapeutic
strategies in atherosclerosis (14).
In survivors of acute coronary syndromes, the burst of
systemic inﬂammation aimed at repairing the injured heart
might be responsible for the high early rate of recurrent
cardiovascular events. In apolipoprotein E knockout mice
with atherosclerosis, experimental myocardial infarction (MI)
induced extramedullary monocytopoiesis, and an increase in
the number of monocytes and macrophages within athero-
sclerotic plaques, associated with larger lesion size, increased
necrotic cores, and decreased ﬁbrous cap thickness (15).
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1132Diabetes, intraplaquehemorrhage,
and haptoglobin. Free hemoglo-
bin after intraplaque hemorrhage
can stimulate the differentiation
of macrophages into a phenotype
characterized by CD163 expres-
sion and decreased intracellular
iron, reduced reactive oxygen
species, and resistance to choles-
terol loading (16). Haptoglobin is
responsible for neutralizing the
deleterious effects of free hemo-
globin through interaction with
the macrophage CD163 scav-
enger receptor, and clinical and
experimental studies have docu-
mented an inferior protective
ability of the haptoglobin 2-2
phenotype, particularly in dia-
betes. Peripheral plaques fromdiabetic patients with the haptoglobin 2-2 genotype exhibited
reduced CD163 expression and an increased oxidative and
inﬂammatory pattern (17). Human haptoglobin 2-2 aortic
plaques also demonstrated higher expression of oxidation-
speciﬁc epitopes (Fig. 4) and increased apoptosis of mac-
rophages and smooth muscle cells (18). In addition, 2
independent large prospective studies identiﬁed the hapto-
globin 2-2 genotype as a marker of increased cardiovascular
risk in individuals with elevated concentration of glycated
hemoglobin (19).Early Detection and Risk Stratiﬁcation
Traditional risk factors and lipid markers. Although the
prevalence of some risk factors has decreased over the last
decades, their impact on outcome when present has remained
remarkably unchanged over the past 40 years (7), emphasizing
the value of primordial prevention. Life expectancy free from
CVD was substantially longer for individuals with optimal
risk factor proﬁles than for those with >1 major risk factor
(Fig. 5, Table 1) (8). Similarly, a strong relationship was noted
between the number of ideal cardiovascular health metrics and
reduced CVDmortality and morbidity across different ethnic
groups (9,20). Mendelian randomization studies emphasized
the relevance of lifelong exposure to low-density lipoprotein
(LDL) cholesterol as a risk factor for CHD (21). On the basis
of data from >165,000 apparently healthy participants in 37
prospective cohorts, the addition of apolipoprotein B and A-I,
lipoprotein(a), or lipoprotein associated phospholipase A2
mass to models containing total and high-density lipoprotein
(HDL) cholesterol enhanced risk prediction but led to net risk
reclassiﬁcation improvements of <1% (22). Similarly, the
ability of LDL apolipoprotein or particle measurements to
predict events was comparable to that of LDL cholesterol
concentrations in individuals with prior CVD or high risk
(23). However, quantiﬁcation of apolipoprotein B and non-HDL cholesterol in statin-treated patients (24,25) or of
HDL particle numbers (23,26) might provide additive
prognostic value. Although the long-term protective impli-
cations of higher HDL concentrations were again conﬁrmed
(27), Mendelian randomization analyses questioned the
existence of a consistent relationship between plasmatic HDL
cholesterol levels and risk of MI (28). With respect to obesity,
an investigation of>15,000 patients with CHD reported that
mortality was highest for those with normal body mass index
but central obesity (Fig. 6) (29).
Nontraditional risk factors. A family history of premature
CHD or cardiovascular death was associated with an
approximately 50% higher long-term risk of CVD, even
after adjustment for conventional risk factors (30,31). In 1
study, the presence of chronic kidney disease (deﬁned as an
estimated glomerular ﬁltration rate <60 ml/min/1.73 m2)
and proteinuria conferred a risk of MI similar to that of
diabetes, supporting its consideration as a CHD equivalent
(32). A meta-analysis of 34 studies identiﬁed signiﬁcant
associations between exposure to most air pollutants and MI
and estimated that up to 4.5% of cases might be attributable
to pollution (33).
Serum biomarkers. A meta-analysis of 52 prospective
studies including nearly 250,000 individuals without known
CVD tested the ability of high-sensitivity C-reactive protein
(CRP) or ﬁbrinogen to reﬁne prediction of major cardio-
vascular events. These biomarkers yielded net reclassiﬁcation
improvements of only 1.5% and 0.8%, respectively, and were
estimated to help prevent 1 additional event over 10 years for
every 400 to 500 people screened (34). However, in a case-
control study of the Women’s Health Initiative, the Rey-
nolds score (which incorporates CRP, glycated hemoglobin,
and family history of premature MI) outperformed the
Framingham and Adult Treatment Panel III scores for
cardiovascular risk stratiﬁcation (35). A meta-analysis of 19
prospective studies and >65,000 individuals with and
without CVD reported increasing risk of major events with
decreasing serum concentrations of 25-hydroxy-vitamin D
(36). Other serum markers that demonstrated independent
and prospective associations with cardiovascular events
included adipocyte fatty acid–binding protein (37), pro-
neurotensin (38), plasma neutrophil gelatinase–associated
lipocalin (39), microRNAs (40), monocyte subtypes (14),
and markers of oxidative (41) or cardiovascular stress (42).
Finally, a report from the Framingham Offspring Study
identiﬁed associations between multiple biomarkers related
to CVD with stroke and subclinical brain injury (43).
Genetic markers and metabolomics. In a large study in
the general population, reduced telomere length demon-
strated independent but modest associations with incident
CHD or death (44). An analysis of >25,000 individuals
conﬁrmed that many polymorphisms that confer higher
cardiovascular risk show no associations with traditional
and novel risk markers, suggesting their participation in
alternative and poorly understood pathways for athero-
thrombosis (45). This was also shown for polymorphisms in
Figure 1 Global Death Ranks by Cause and Their Percentage Change in 1990 and 2010
Reproduced with permission from Lozano et al. (1). COPD ¼ chronic obstructive pulmonary disease; HIV/AIDS ¼ human immunodeﬁciency virus/acquired immunodeﬁciency
syndrome; UI ¼ uncertainty interval.
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1133chromosome 9p21, which additionally were linked to
increased risk for MI, higher coronary artery calcium scores,
and increased abdominal aorta diameters in the general
population (46). In a large meta-analysis of patients
undergoing angiography, chromosome 9p21 variants were
also associated with higher coronary disease burden but not
increased MI risk in the presence of established CHD (47).Table 1 Deﬁnitions of Optimal, Suboptimal, Elevated, and Major Risk
Deﬁnition
Blood Pressure
(mm Hg) Total Cholesterol (mg/dl) Diabetes
Optimal <120/80 <180 No
Suboptimal* 120–139/80–89 180–199 No
Elevated* 140–159/90–99 200–239 No
Major* >160/100 or treated >240 or treated Yes
*A proﬁle is present if any of the above abnormalities in any of the 4 risk factors is present. Current sm
cardiovascular disease (CVD) are presented as ranges of averages that vary with age, sex, and numberA novel variant of the Y chromosome linked to immune
pathways was deemed to increase CHD risk by 50%,
independent of traditional risk factors; this ﬁnding might
partly explain sex-based differences in CVD (48). Investi-
gators developed various multi-loci genetic scores to enhance
risk prediction beyond conventional approaches in individ-
uals free from CVD; although some discriminative abilityFactor Proﬁles
Current Smoking Prevalence (%) Lifetime Risk of CVD Death (%)
No 3.2 1.4–29.5
No 9.0 12.2–31.2
No 19.7 15.3–38.2
Yes 68.2 16.7–49.5
oking and diabetes qualify as major risk factors. Lifetime risks of death related to atherosclerotic
of risk factors. Reprinted with permission from Berry et al. (7).
Figure 2
Prevalence of Ideal, Intermediate, and Poor Cardiovascular Health Metrics in the United States in 2006,
and Projections for 2020
The ﬁgure also shows the American Heart Association 2020 Strategic Impact Goals targets. Poor metrics include current smoking, diet score ¼ 0 to 1, no physical activity,
body mass index 30 kg/m2, fasting glucose 126 mg/dl or known diabetes with hemoglobin A1c 7%, total cholesterol 240 mg/dl (or 200 if treated), and blood pressure
>140/90 mm Hg. Ideal metrics include having never smoked or having quit for at least 12 months, diet score 4 to 5, 75 min/week of vigorous or 150 min/week of
moderate-intensity exercise, body mass index <25 kg/m2, fasting glucose <100 mg/dl, total cholesterol <200 mg/dl, and blood pressure <120/80 mm Hg. Intermediate
metrics fall in between the ideal and poor categories. Reproduced with permission from Huffman et al. (10).
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1134was noted, improvements were generally modest and
inconsistent (49,50). Conversely, blood-based scores of gene
expression or metabolite proﬁles in mostly symptomatic
patients were independently associated with obstructive
CHD or outcomes (51,52).
Invasive imaging. A substudy of PROSPECT (Providing
Regional Observations to Study Predictors of Events in the
Coronary Tree) evaluated calciﬁed coronary nodules with
intravascular ultrasound (IVUS) in patients with acute
coronary syndromes. Their prevalence was 17%/artery and
30%/patient, and interestingly, they were independently
associated with fewer events during follow-up (53). Bycontrast, serial IVUS studies identiﬁed spotty calciﬁcation
(54) or large plaque burden and low shear stress (55) as
markers of accelerated disease progression. The high rate of
healing (75%) of nonculprit thin-cap ﬁbroatheromas in 12
months previously reported in a predominantly stable pop-
ulation could not be replicated in the setting of ST-segment
elevation MI, where only 22% evolved into more stable
phenotypes, and most additionally progressed (56). Statin
therapy was associated not only with reductions in coronary
atheroma volume but also decreases in lipid component and
increases in ﬁbrous cap thickness as determined by IVUS
and optical coherence tomography (57). Also on optical
Figure 3
Relationship Between Nonclassical Monocytes
Serum Levels and Cardiovascular Events
Events encompass cardiovascular death, myocardial infarction, or ischemic
stroke. Reproduced with permission from Rogacev et al. (14).
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1135coherence tomography, the presence of thin-cap ﬁbroa-
theromas and microchannels (Fig. 7), believed to represent
neovessels, were independent predictors of subsequent
progression of plaques causing nonsigniﬁcant stenoses (58).
Noninvasive imaging. Quantiﬁcation of common carotid
intima-media thickness (CIMT) in the general population
leads to a modest net reclassiﬁcation improvement of 0.8%
(3.6% in intermediate-risk patients) when added to the
Framingham risk score for the prediction of MI or stroke,
according to a meta-analysis of 14 cohorts and >45,000
individuals (59). Another meta-analysis conﬁrmed that the
addition of carotid plaque presence improves the ability to
predict MI signiﬁcantly (60). With 3-dimensional analysis
methodology (Fig. 8), carotid plaque burden had the
strongest correlation with coronary calcium score when
compared with the CIMT, ankle-brachial index, and
abdominal aortic diameter in the High Risk Plaque Biomage
study. The prevalences of subclinical atherosclerosis in 6,101
asymptomatic individuals with mostly intermediate Fra-
mingham risk score were 78% for carotid plaque, 68% for
positive calcium score, 28% for dilated abdominal aorta, and
10% for abnormal ankle-brachial index (61).
In 1,330 intermediate-risk participants without diabetes in
the MESA (Multi-Ethnic Study of Atherosclerosis), the
addition of the coronary calcium score as measured with
computed tomography (CT) to the Framingham risk score
outperformed CRP, family history, ﬂow-mediated vasodila-
tation, CIMT, and ankle-brachial index for the prediction of
incident CHD and CVD (Fig. 9). For the 2 outcomes, netrisk reclassiﬁcation improvements with calcium scoring were
66% and 47%, respectively (62). Similar results were reported
in nearly 6,000 individuals of the Rotterdam Study in whom
calcium score, CIMT, ankle-brachial index, pulse wave
velocity, and multiple serum biomarkers were measured.
Calcium scoring provided the best prognostic accuracy (net
reclassiﬁcation index 19%, 39% for those at intermediate
risk) followed by N-terminal pro-brain natriuretic peptide
(63). Addition of CT angiography to the calcium score
minimally improved predictive ability in asymptomatic
individuals from a large registry (64).
In a population-based study of 1,006 individuals undergoing
carotid high-resolution magnetic resonance imaging (MRI),
lipid cores and intraplaque hemorrhage were present in 25% of
plaques. Current smoking and hypertension were associated
with intraplaque bleeding and hypercholesterolemia with the
presence of a lipid core (65). Another population-based study
performed contrast-enhanced cardiac MRI in 936 elderly
individuals. The presence of an unrecognizedMI was noted in
17%, and was independently associated with higher risk of
death (66). Finally, microwave radiometry, a novel noninvasive
method for temperature quantiﬁcation, was applied in human
carotid arteries; increased temperature correlated with both
inﬂammation and neovascularization (67).
Molecular imaging. 18F-ﬂuorodeoxyglucose positron emission
tomography (PET) of the carotid circulation depicted increased
inﬂammation in diabetic atherosclerosis in a study of 134
patients with known or suspected CVD (68). In addition, novel
PET radiotracers for imaging vascular inﬂammation (69), active
calciﬁcation (70), and nicotinic acetylcholine receptors (71) were
used in early human trials. Ultrasound with microbubbles
conjugated to an antibody speciﬁc for activated glycoprotein IIb/
IIIa could detect arterial thrombosis and monitor thrombolysis
in mice (72). Also, studies using MRI and PET/CT demon-
strated reductions in disease progression and inﬂammation
induced by liver X receptor agonists in experimental athero-
sclerosis (73,74).
Prevention and Treatment
The impact of nonpharmacological preventive interventions
was the topic of several investigations. According to a meta-
analysis of 45 studies, comprehensive smoke-free legislation
is associated with 15% and 16% reductions in hospital stays/
deaths related to coronary events and strokes, respectively
(75). In a study of nearly 12,000 Japanese patients with
established CHD, exercise and dietary interventions
conferred an approximate 35% reduction in mortality after
adjusting for conventional risk factors and medical therapy
(76). Similarly, high-quality dietary patterns were associated
with fewer CVD events in patients 55 years of age with
prior CVD or diabetes, regardless of the use of secondary
prevention drugs (77). A prospective, randomized, multi-
center trial of 7,447 high-risk individuals without known
CVD was stopped prematurely after 4.8 years, because of
28% to 30% adjusted risk reductions of incident events
Figure 4 Increased Expression of Oxidation-Speciﬁc Epitopes Associated With the Haptoglobin (Hp)2-2 Genotype
Immunostaining of human aortic atherosclerotic lesions shows increased expression of oxidized phospholipids (OxPLs, EO6) and malondialdehyde (MDA)-like oxidation-speciﬁc
epitopes in plaques with the (Hp)2-2 genotype (A and D) compared with control plaques (B and E). The graph bars shown in C and F demonstrate the different density of
oxidation-speciﬁc epitopes quantitatively. Reproduced with permission from Purushothaman et al. (18).
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1136associated with aMediterranean diet supplemented with olive
oil or mixed nuts when compared with a control diet (78). In
the treatment of severe obesity, bariatric surgery emerged as
a powerful therapeutic approach to improve cardiovascular
outcomes. In >4,000 subjects enrolled in a prospective,
nonrandomized study, bariatric surgery was associated with
adjusted relative risk reductions of 53% (p ¼ 0.002) and 33%
(p < 0.001) in cardiovascular mortality and major events,
respectively, after a median follow-up of 14.7 years (79).
Several original investigations and meta-analyses examined
pharmacological interventions for cardiovascular prevention.
A review of 20 studies with >375,000 patients found
poor overall adherence to cardiovascular medications: 42% to
61% in primary prevention; and 62% to 76% in secondary
prevention (80). Moreover, only 8% to 23% of diabetic
patients enrolled in large randomized trials of secondary
prevention achieved guideline-recommended targets for
systolic blood pressure, LDL cholesterol, glycated he-
moglobin, and smoking cessation (81). Two publications
re-emphasized the reductions in cardiovascular events asso-
ciated with angiotensin-converting enzyme inhibitors and
angiotensin receptor blockers in patients with atherosclerosis,
even in the absence of systolic heart failure, hypertension,
or diabetes (82,83). Another meta-analysis revisited the op-
timal treatment of hypertensive patients with diabetes andconﬁrmed no reductions in mortality or MI but small de-
creases in stroke rates with intensive blood-pressure lowering
(to <130/80 mm Hg) (84). Interestingly, a similar pattern
was noted also for nondiabetic patients in a secondary analysis
of a large trial of high-risk patients (85). In another study,
12,537 patients with dysglycemia and elevated cardiovascular
risk were randomized to glycemic control with insulin versus
standard care. Insulin for a median of 6.2 years led to near-
normal glucose and glycated hemoglobin levels and reduced
the incidence of new-onset diabetes but had no net effect on
cardiovascular outcomes (86). In the same trial, omega-3 fatty
acid supplementation versus placebo also failed to reduce
major cardiovascular events (87), in agreement with a meta-
analysis of 20 studies in both primary and secondary
prevention (88). In addition, a randomized, non–placebo-
controlled study of 532 stable CHD patients reported that
low-dose colchicine added to statin and antiplatelet agents
might be effective in reducing cardiovascular events (hazard
ratio: 0.29; p < 0.001) (89).
Lipid management. Although statins are often not
prescribed for low-risk patients, a meta-analysis of 27 studies
demonstrated 30% relative risk reductions in CVD and
potential cost-effectiveness in this population (90). Beneﬁts of
statin therapy offset the potential associated risk of new-onset
diabetes in both primary (91) and secondary prevention (92)
Figure 5 CVD-Free Survival and Total Survival After CVD Events
Stratiﬁed by age, sex, and risk proﬁle. See Table 1 for deﬁnitions. Reproduced with permission from Wilkins et al. (8). CVD ¼ cardiovascular disease.
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1137settings. A potential alternative for LDL cholesterol reduction
is the inhibition of proprotein convertase subtilisin/kexin type
9 with resulting decreased degradation of hepatocyte LDL
receptors. Several phase 2 studies tested human monoclonal
antibodies against pre-protein convertase subtilisin/kexin type
9 and reported average 40% to 70% reductions in LDL
cholesterol levels (even when added to statin or ezetimibe
regimens) and acceptable safety proﬁles (93–95).
The atheroprotective effects of HDL-related therapies
continued to be controversial in 2012. In an experimental
model of atherosclerosis, the administration of either
recombinant wild-type or Milano-HDL led to regression of
atherosclerosis, with the latter demonstrating more potent
anti-inﬂammatory and plaque-stabilizing effects (96). In
contrast to recent negative studies, a review of 11 random-
ized trials with nearly 10,000 patients identiﬁed a signiﬁcant
34% relative reduction of CVD events with the use of nia-
cin, which was however unrelated to its ability to increase
HDL cholesterol (97). After the increased risk associated
with torcetrapib despite substantial increases in plasma HDL
concentrations, the dal-OUTCOMES (Effects of Dalce-
trapib in Patients with a Recent Acute Coronary Syndrome)
trial (98) compared dalcetrapib, another cholesteryl ester
transfer protein inhibitor, with placebo in 15,871 patients
with a recent acute coronary syndrome. Despite increasing
HDL levels by up to 40%, the trial was terminated earlybecause of lack of beneﬁt from dalcetrapib. These ﬁndings
are in line with dal-VESSEL (Safety and Efﬁcacy of
Dalcetrapib on Endothelial Function Using Brachial Artery
Flow-Mediated Vasodilation), where dalcetrapib caused no
improvements in endothelial function as measured by
ﬂow-mediated vasodilatation (99).
Antithrombotic therapy. Addressing the duration of clo-
pidogrel treatment, a Danish nationwide registry of almost
30,000 post-MI patients indicated increased risk of death or
recurrent MI for the ﬁrst 3 months after discontinuation of
clopidogrel after 1 year for those who had undergone
percutaneous coronary intervention (PCI) but not for those
treated medically (100). However, other studies suggested
that discontinuation of dual antiplatelet therapy early during
the ﬁrst year after drug-eluting stent implantation might be
safe (101,102). To address the optimal antithrombotic
approach in PCI patients who require dual antiplatelet
inhibition and also have an indication for anticoagulation,
a study of 573 patients compared the addition of clopidogrel
plus aspirin versus clopidogrel alone with oral anticoagulants
for 1 year. Anticoagulation plus clopidogrel led to a 64%
relative reduction in bleeding episodes (p < 0.0001) in
comparison with triple therapy without a concomitant
increase in thrombotic events (103). Clopidogrel (75 mg/
day) plus aspirin was compared with prasugrel (5 to 10 mg/
day) plus aspirin in 7,243 patients with <75 years of age,
Figure 6
Five-Year Mortality in CHD According to Weight and
Central Obesity
Normal or abnormal weight is indicated by the body mass index (BMI). Central
obesity is quantiﬁed with the waist circumference. Similar results are obtained
with the waist/hip ratio (not shown). Reproduced with permission from
Coutinho et al. (29). CHD ¼ coronary heart disease.
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1138unstable angina, or non–ST-segment elevation MI not
receiving revascularization in the TRILOGY ACS (Tar-
geted Platelet Inhibition to Clarify the Optimal Strategy to
Medically Manage Acute Coronary Syndromes) trial. In
contrast to prior studies that demonstrated beneﬁts in
patients undergoing PCI, prasugrel did not decrease the rate
of the primary endpoint (cardiovascular death, MI or stroke:
hazard ratio: 0.91; 95% conﬁdence interval: 0.79 to 1.05;
p ¼ 0.21) after a follow-up of up to 2.5 years. OfFigure 7
Optical Coherence Tomography of Nonsigniﬁcant
Coronary Plaques
Two features associated with plaque progression are depicted: a thin ﬁbrous cap
(A, arrow) surrounding a lipid pool (Lp); and the presence of microchannels (B,
arrowhead). Modiﬁed with permission from Uemura et al. (58).importance, there were no increases in major bleeding either
(104). Vorapaxar, another antithrombotic agent that selec-
tively inhibits platelet protease-activated receptor-1, was
tested for secondary prevention in the TRA 2P–TIMI 50
(Thrombin Receptor Antagonist in Secondary Prevention
of Atherothrombotic Ischemic Events–Thrombolysis In
Myocardial Infarction 50) trial. A total of 26,449 stable
patients with established CVD deﬁned as prior MI, stroke,
or peripheral artery disease were randomized to vorapaxar or
placebo on top of standard antiplatelet therapy. After
a median follow-up of 2.5 years, vorapaxar led to reductions
in major cardiovascular events (13% relative reduction; p <
0.001) but a 66% relative increase in moderate to severe
bleeding (p < 0.001), including a near-doubling of intra-
cranial hemorrhage, which led to no net outcome
improvement (105). Although the risk of intracranial
bleeding was highest in those with prior stroke (105), net
beneﬁts were identiﬁed in the subgroup of patients with
prior MI, particularly if younger than 75 years and weighing
>60 kg (106).
The role of platelet reactivity testing to guide anti-
platelet therapy remained questionable. A substudy of the
TRILOGY ACS trial with 2,654 participants found con-
sistent reductions in platelet aggregation with prasugrel in
comparison with clopidogrel, but the observed univariate
associations between high on-treatment platelet reactivity
(HTPR) with outcomes did not remain in multi-adjusted
models (107). The ARCTIC (Conventional Antiplatelet
Strategy versus a Monitoring-guided Strategy for Drug-
Eluting Stent Implantation and of Treatment Interruption
versus Continuation One Year after Stenting) trial
randomized a mixed population of 2,440 patients with stable
and unstable CHD treated with drug-eluting stents to
a standard antiplatelet regimen versus an intensive one
guided by HTPR. At 1 year, there were no signiﬁcant
differences in cardiovascular events, stent thrombosis, or
bleeding risk (108). Another investigation that randomized
stable patients with residual HTPR after elective PCI to
prasugrel or clopidogrel again demonstrated more potent
antiplatelet effects with prasugrel but was stopped prema-
turely, due to lower-than-expected event rates (109). Finally,
platelet reactivity did not predict outcomes in 771 stable,
medically treated CVD patients (110). Overall, these studies
do not support routine use of reactivity testing, although
substitution of clopidogrel for prasugrel could be reasonable
in higher-risk cases (i.e., those with recurrent events).
Revascularization in stable CHD. Previous randomized
trials have demonstrated no overall beneﬁts from PCI
added to medical therapy in patients with stable CHD.
However, the FAME 2 (Fractional Flow Reserve versus
Angiography for Multivessel Evaluation 2) trial tested the
hypothesis that PCI with drug-eluting stents would be
superior to medical therapy in patients with stenoses
causing ischemia as determined by reduced fractional ﬂow
reserve (0.8). After randomization of 888 patients and
mean follow-up of 7 months, the trial was terminated
Figure 8 Quantiﬁcation of Plaque Burden With Ultrasound
Serial cross-sectional imaging of the carotid artery along the neck allows for quantiﬁcation of plaque area at multiple levels and determination of total plaque burden.
Reproduced with permission from Sillesen et al. (61).
Figure 9 Predictive Ability of Different Biomarkers in Intermediate-Risk Individuals
Receiver operator characteristic curves for incident coronary heart disease (A) and cardiovascular disease (B) demonstrate superior discrimination of coronary calcium scoring
when added to the FRS than other common markers of risk. Reproduced with permission from Yeboah et al. (62).
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Figure 10
Incidence of the Primary Efﬁcacy Endpoint in
the FREEDOM Trial
Cumulative incidence curves for the primary composite outcome (death, nonfatal
myocardial infarction, or nonfatal stroke). CABG ¼ coronary artery bypass grafting;
FREEDOM ¼ Future Revascularization Evaluation in Patients with Diabetes
Mellitus: Optimal Management of Multivessel Disease; PCI ¼ percutaneous
coronary intervention. Reproduced with permission from Farkouh (115).
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1140prematurely due to excess events in the medical therapy
arm (12.7% vs. 4.3%; hazard ratio with PCI: 0.32;
p < 0.001). This was driven by an 87% relative reduction in
the need for urgent revascularization, whereas no differ-
ences were observed in the rates of death or MI, the 2 other
components of the primary endpoint (111).
With regard to PCI versus surgical revascularization, the
5-year results of the SYNTAX (SYNergy between percu-
taneous coronary intervention with TAXus and cardiac
surgery) trial were reported. The extended follow-up
conﬁrmed that surgery is the revascularization method of
choice in patients with multivessel disease and complex
coronary anatomy (intermediate or high SYNTAX scores),
because of sustained event reductions, whereas PCI with
drug-eluting stents is an appropriate alternative in the rest of
cases (112). A modiﬁed SYNTAX score that includes not
only angiographic but also clinical characteristics was addi-
tionally proposed and validated (113). Publications from 2
large studies revisited the role of revascularization in diabetic
stable CHD. The BARI 2D (Bypass Angioplasty Re-
vascularization Investigation 2 Diabetes) trial previously
showed that the addition of revascularization did not
improve survival in comparison with intensive medical
therapy alone in type 2 diabetic patients with obstructive
coronary disease. However, cardiovascular events were lower
in those assigned to surgical revascularization by preference
of the physician. A secondary analysis indicated that this
reduction in events was restricted to those with higher
cardiovascular risk, lower ejection fraction, and more
complex coronary anatomy, whereas revascularization did
not improve outcomes in the lower-risk surgical group orany of the PCI subgroups (114). Although the BARI 2D
trial employed mostly bare-metal stents, the prospective,
multicenter FREEDOM (Future Revascularization Evalu-
ation in Patients with Diabetes Mellitus: Optimal Man-
agement of Multivessel Disease) trial randomized 1,900
patients with diabetes and multivessel coronary artery disease
to revascularization with either bypass grafting or drug-
eluting stents on top of intensive medical therapy. The
5-year rate of the primary composite outcome was 30%
lower in the surgical group (Fig. 10), because of reductions
in all-cause mortality (10.9% vs. 16.3%; p ¼ 0.049) and MI
(6% vs. 13.9%; p < 0.001), at the cost of a slight increase in
stroke (5.2% vs. 2.4%; p ¼ 0.03). These results were
consistent across levels of angiographic complexity or left
ventricular systolic function (115). Despite higher initial
costs, surgical revascularization was deemed cost-effective in
comparison with PCI in the long term (116).Reprint requests and correspondence: Dr. Valentin Fuster,
Cardiovascular Institute, Mount Sinai Hospital, One Gustave L.
Levy Place, Box 1030, New York, New York 10029. E-mail:
valentin.fuster@mssm.edu.REFERENCES
1. Lozano R, Naghavi M, Foreman K, et al. Global and regional
mortality from 235 causes of death for 20 age groups in 1990 and
2010: a systematic analysis for the Global Burden of Disease Study
2010. Lancet 2012;380:2095–128.
2. Murray CJ, Vos T, Lozano R, et al. Disability-adjusted life years
(DALYs) for 291 diseases and injuries in 21 regions, 1990–2010:
a systematic analysis for the Global Burden of Disease Study 2010.
Lancet 2012;380:2197–223.
3. Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of
burden of disease and injury attributable to 67 risk factors and risk
factor clusters in 21 regions, 1990–2010: a systematic analysis for the
Global Burden of Disease Study 2010. Lancet 2012;380:2224–60.
4. Lee IM, Shiroma EJ, Lobelo F, Puska P, Blair SN, Katzmarzyk PT.
Effect of physical inactivity on major non-communicable diseases
worldwide: an analysis of burden of disease and life expectancy. Lancet
2012;380:219–29.
5. Thompson RC, Allam AH, Lombardi GP, et al. Atherosclerosis
across 4000 years of human history: the Horus study of four ancient
populations. Lancet 2013;381:1211–22.
6. Webber BJ, Seguin PG, Burnett DG, Clark LL, Otto JL. Prevalence
of and risk factors for autopsy-determined atherosclerosis among US
service members, 2001–2011. JAMA 2012;308:2577–83.
7. Berry JD, Dyer A, Cai X, et al. Lifetime risks of cardiovascular
disease. N Engl J Med 2012;366:321–9.
8. Wilkins JT, Ning H, Berry J, Zhao L, Dyer AR, Lloyd-Jones DM.
Lifetime risk and years lived free of total cardiovascular disease.
JAMA 2012;308:1795–801.
9. Yang Q, Cogswell ME, Flanders WD, et al. Trends in cardiovascular
health metrics and associations with all-cause and CVD mortality
among US adults. JAMA 2012;307:1273–83.
10. Huffman MD, Capewell S, Ning H, Shay CM, Ford ES, Lloyd-
Jones DM. Cardiovascular health behavior and health factor changes
(1988–2008) and projections to 2020: results from the National Health
and Nutrition Examination Surveys. Circulation 2012;125:2595–602.
11. Guo F, He D, Zhang W, Walton RG. Trends in prevalence,
awareness, management, and control of hypertension among United
States adults, 1999 to 2010. J Am Coll Cardiol 2012;60:599–606.
12. Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity
and trends in the distribution of body mass index among US adults,
1999–2010. JAMA 2012;307:491–7.
JACC Vol. 62, No. 13, 2013 Sanz et al.
September 24, 2013:1131–1143 The Year in Atherothrombosis
114113. Thun MJ, Carter BD, Feskanich D, et al. 50-year trends in smoking-
relatedmortality in the United States. NEngl JMed 2013;368:351–64.
14. Rogacev KS, Cremers B, Zawada AM, et al. CD14þþCD16þ
monocytes independently predict cardiovascular events: a cohort study
of 951 patients referred for elective coronary angiography. J Am Coll
Cardiol 2012;60:1512–20.
15. Dutta P, Courties G, Wei Y, et al. Myocardial infarction accelerates
atherosclerosis. Nature 2012;487:325–9.
16. Finn AV, Nakano M, Polavarapu R, et al. Hemoglobin directs
macrophage differentiation and prevents foam cell formation in
human atherosclerotic plaques. J Am Coll Cardiol 2012;59:166–77.
17. PurushothamanM, Krishnan P, Purushothaman KR, et al. Genotype-
dependent impairment of hemoglobin clearance increases oxidative and
inﬂammatory response in human diabetic atherosclerosis. Arterioscler
Thromb Vasc Biol 2012;32:2769–75.
18. Purushothaman KR, Purushothaman M, Levy AP, et al. Increased
expression of oxidation-speciﬁc epitopes and apoptosis are associated
with haptoglobin genotype: possible implications for plaque progres-
sion in human atherosclerosis. J Am Coll Cardiol 2012;60:112–9.
19. Cahill LE, Levy AP, Chiuve SE, et al. Haptoglobin genotype is
a consistent marker of coronary heart disease risk among individuals with
elevated glycosylated hemoglobin. J Am Coll Cardiol 2013;61:728–37.
20. Dong C, Rundek T, Wright CB, Anwar Z, Elkind MS, Sacco RL.
Ideal cardiovascular health predicts lower risks of myocardial infarc-
tion, stroke, and vascular death across whites, blacks, and Hispanics:
the northern Manhattan study. Circulation 2012;125:2975–84.
21. Ference BA, Yoo W, Alesh I, et al. Effect of long-term exposure to
lower low-density lipoprotein cholesterol beginning early in life on the
risk of coronary heart disease: a Mendelian randomization analysis.
J Am Coll Cardiol 2012;60:2631–9.
22. Di Angelantonio E, Gao P, Pennells L, et al. Lipid-related markers
and cardiovascular disease prediction. JAMA 2012;307:2499–506.
23. Parish S, Offer A, Clarke R, et al. Lipids and lipoproteins and risk of
different vascular events in the MRC/BHF Heart Protection Study.
Circulation 2012;125:2469–78.
24. Boekholdt SM, Arsenault BJ, Mora S, et al. Association of LDL
cholesterol, non-HDL cholesterol, and apolipoprotein B levels with
risk of cardiovascular events among patients treated with statins:
a meta-analysis. JAMA 2012;307:1302–9.
25. Robinson JG, Wang S, Jacobson TA. Meta-analysis of comparison of
effectiveness of lowering apolipoprotein B versus low-density lipo-
protein cholesterol and nonhigh-density lipoprotein cholesterol for
cardiovascular risk reduction in randomized trials. Am J Cardiol 2012;
110:1468–76.
26. Mackey RH, Greenland P, Goff DC Jr., Lloyd-Jones D, Sibley CT,
Mora S. High-density lipoprotein cholesterol and particle concen-
trations, carotid atherosclerosis, and coronary events: MESA (multi-
ethnic study of atherosclerosis). J Am Coll Cardiol 2012;60:508–16.
27. Rahilly-Tierney C, Sesso HD, Michael Gaziano J, Djousse L. High-
density lipoprotein and mortality before age 90 in male physicians.
Circ Cardiovasc Qual Outcomes 2012;5:381–6.
28. Voight BF, Peloso GM, Orho-Melander M, et al. Plasma HDL
cholesterol and risk of myocardial infarction: a Mendelian random-
isation study. Lancet 2012;380:572–80.
29. Coutinho T, Goel K, Correa de Sa D, et al. Combining body mass
index with measures of central obesity in the assessment of mortality
in subjects with coronary disease: role of “normal weight central
obesity”. J Am Coll Cardiol 2012;61:553–60.
30. Bachmann JM, Willis BL, Ayers CR, Khera A, Berry JD. Association
between family history and coronary heart disease death across long-
term follow-up in men: the Cooper Center Longitudinal Study.
Circulation 2012;125:3092–8.
31. Ranthe MF, Carstensen L, Oyen N, et al. Family history of premature
death and risk of early onset cardiovascular disease. J Am Coll Cardiol
2012;60:814–21.
32. Tonelli M, Muntner P, Lloyd A, et al. Risk of coronary events in
people with chronic kidney disease compared with those with dia-
betes: a population-level cohort study. Lancet 2012;380:807–14.
33. Mustaﬁc H, Jabre P, Caussin C, et al. Main air pollutants and
myocardial infarction: a systematic review and meta-analysis. JAMA
2012;307:713–21.
34. Kaptoge S, Di Angelantonio E, Pennells L, et al. C-reactive protein,
ﬁbrinogen, and cardiovascular disease prediction. N Engl J Med 2012;
367:1310–20.35. Cook NR, Paynter NP, Eaton CB, et al. Comparison of the Fra-
mingham and Reynolds Risk scores for global cardiovascular risk
prediction in the multiethnic Women’s Health Initiative. Circulation
2012;125:1748–56, S1–11.
36. Wang L, Song Y, Manson JE, et al. Circulating 25-hydroxy-vitamin
D and risk of cardiovascular disease: a meta-analysis of prospective
studies. Circ Cardiovasc Qual Outcomes 2012;5:819–29.
37. von Eynatten M, Breitling LP, Roos M, Baumann M,
Rothenbacher D, Brenner H. Circulating adipocyte fatty acid-binding
protein levels and cardiovascular morbidity and mortality in patients
with coronary heart disease: a 10-year prospective study. Arterioscler
Thromb Vasc Biol 2012;32:2327–35.
38. Melander O, Maisel AS, Almgren P, et al. Plasma proneurotensin
and incidence of diabetes, cardiovascular disease, breast cancer, and
mortality. JAMA 2012;308:1469–75.
39. Daniels LB, Barrett-Connor E, Clopton P, Laughlin GA, Ix JH,
Maisel AS. Plasma neutrophil gelatinase-associated lipocalin is
independently associated with cardiovascular disease and mortality in
community-dwelling older adults: The Rancho Bernardo Study. J Am
Coll Cardiol 2012;59:1101–9.
40. Zampetaki A, Willeit P, Tilling L, et al. Prospective study on
circulating MicroRNAs and risk of myocardial infarction. J Am Coll
Cardiol 2012;60:290–9.
41. Tsimikas S, Willeit P, Willeit J, et al. Oxidation-speciﬁc biomarkers,
prospective 15-year cardiovascular and stroke outcomes, and net reclassi-
ﬁcation of cardiovascular events. J Am Coll Cardiol 2012;60:2218–29.
42. Wang TJ, Wollert KC, Larson MG, et al. Prognostic utility of novel
biomarkers of cardiovascular stress: the Framingham Heart Study.
Circulation 2012;126:1596–604.
43. Pikula A, Beiser AS, DeCarli C, et al. Multiple biomarkers and risk of
clinical and subclinical vascular brain injury: the Framingham
Offspring Study. Circulation 2012;125:2100–7.
44. Weischer M, Bojesen SE, Cawthon RM, Freiberg JJ, Tybjaerg-
Hansen A, Nordestgaard BG. Short telomere length, myocardial
infarction, ischemic heart disease, and early death. Arterioscler
Thromb Vasc Biol 2012;32:822–9.
45. Angelakopoulou A, Shah T, Sofat R, et al. Comparative analysis of
genome-wide association studies signals for lipids, diabetes, and
coronary heart disease: Cardiovascular Biomarker Genetics Collabo-
ration. Eur Heart J 2012;33:393–407.
46. Johnson AD, Hwang SJ, Voorman A, et al. Resequencing and clinical
associations of the 9p21.3 region: a comprehensive investigation in the
Framingham heart study. Circulation 2013;127:799–810.
47. Chan K, Patel RS, Newcombe P, et al. Association between the
chromosome 9p21 locus and angiographic coronary artery disease
burden: a collaborative meta-analysis. J Am Coll Cardiol 2013;61:
957–70.
48. Charchar FJ, Bloomer LD, Barnes TA, et al. Inheritance of coronary
artery disease in men: an analysis of the role of the Y chromosome.
Lancet 2012;379:915–22.
49. Brautbar A, Pompeii LA, Dehghan A, et al. A genetic risk score based
on direct associations with coronary heart disease improves coronary
heart disease risk prediction in the Atherosclerosis Risk in Commu-
nities (ARIC), but not in the Rotterdam and Framingham Offspring,
Studies. Atherosclerosis 2012;223:421–6.
50. Thanassoulis G, Peloso GM, Pencina MJ, et al. A genetic risk score is
associatedwith incident cardiovascular disease and coronary artery calcium:
the Framingham Heart Study. Circ Cardiovasc Genet 2012;5:113–21.
51. Lansky A, Elashoff MR, Ng V, et al. A gender-speciﬁc blood-based
gene expression score for assessing obstructive coronary artery disease
in nondiabetic patients: results of the Personalized Risk Evaluation
and Diagnosis in the Coronary Tree (PREDICT) trial. Am Heart J
2012;164:320–6.
52. Shah SH, Sun JL, Stevens RD, et al. Baseline metabolomic proﬁles
predict cardiovascular events in patients at risk for coronary artery
disease. Am Heart J 2012;163:844–50. e1.
53. Xu Y, Mintz GS, Tam A, et al. Prevalence, distribution, predictors,
and outcomes of patients with calciﬁed nodules in native coronary
arteries: a 3-vessel intravascular ultrasound analysis from Providing
Regional Observations to Study Predictors of Events in the Coronary
Tree (PROSPECT). Circulation 2012;126:537–45.
54. Kataoka Y, Wolski K, Uno K, et al. Spotty calciﬁcation as a marker of
accelerated progression of coronary atherosclerosis: insights from serial
intravascular ultrasound. J Am Coll Cardiol 2012;59:1592–7.
Sanz et al. JACC Vol. 62, No. 13, 2013
The Year in Atherothrombosis September 24, 2013:1131–1143
114255. Stone PH, Saito S, Takahashi S, et al. Prediction of progression of
coronary artery disease and clinical outcomes using vascular proﬁling
of endothelial shear stress and arterial plaque characteristics: the
PREDICTION Study. Circulation 2012;126:172–81.
56. Zhao Z, Witzenbichler B, Mintz GS, et al. Dynamic nature of
nonculprit coronary artery lesion morphology in STEMI: a serial
IVUS analysis from the HORIZONS-AMI trial. J Am Coll Cardiol
Img 2012;6:86–95.
57. Hattori K, Ozaki Y, Ismail TF, et al. Impact of statin therapy on
plaque characteristics as assessed by serial OCT, grayscale and inte-
grated backscatter-IVUS. J Am Coll Cardiol Img 2012;5:169–77.
58. Uemura S, Ishigami K, Soeda T, et al. Thin-cap ﬁbroatheroma and
microchannel ﬁndings in optical coherence tomography correlate with
subsequent progression of coronary atheromatous plaques. Eur Heart J
2012;33:78–85.
59. Den Ruijter HM, Peters SA, Anderson TJ, et al. Common carotid
intima-media thickness measurements in cardiovascular risk predic-
tion: a meta-analysis. JAMA 2012;308:796–803.
60. Inaba Y, Chen JA, Bergmann SR. Carotid plaque, compared with
carotid intima-media thickness, more accurately predicts coronary artery
disease events: a meta-analysis. Atherosclerosis 2012;220:128–33.
61. Sillesen H, Muntendam P, Adourian A, et al. Carotid plaque burden
as a measure of subclinical atherosclerosis: comparison with other tests
for subclinical arterial disease in the High Risk Plaque BioImage
study. J Am Coll Cardiol Img 2012;5:681–9.
62. Yeboah J, McClelland RL, Polonsky TS, et al. Comparison of novel
risk markers for improvement in cardiovascular risk assessment in
intermediate-risk individuals. JAMA 2012;308:788–95.
63. Kavousi M, Elias-Smale S, Rutten JH, et al. Evaluation of newer risk
markers for coronary heart disease risk classiﬁcation: a cohort study.
Ann Intern Med 2012;156:438–44.
64. Cho I, Chang HJ, Sung JM, et al. Coronary computed tomographic
angiography and risk of all-cause mortality and nonfatal myocardial
infarction in subjects without chest pain syndrome from the
CONFIRM Registry (coronary CT angiography evaluation for clin-
ical outcomes: an international multicenter registry). Circulation 2012;
126:304–13.
65. van den Bouwhuijsen QJ, Vernooij MW, Hofman A, Krestin GP, van
der Lugt A, Witteman JC. Determinants of magnetic resonance
imaging detected carotid plaque components: the Rotterdam Study.
Eur Heart J 2012;33:221–9.
66. Schelbert EB, Cao JJ, Sigurdsson S, et al. Prevalence and prognosis of
unrecognized myocardial infarction determined by cardiac magnetic
resonance in older adults. JAMA 2012;308:890–6.
67. Toutouzas K, Grassos C, Drakopoulou M, et al. First in vivo appli-
cation of microwave radiometry in human carotids: a new noninvasive
method for detection of local inﬂammatory activation. J Am Coll
Cardiol 2012;59:1645–53.
68. Bucerius J, Mani V,Moncrieff C, et al. Impact of noninsulin-dependent
type 2 diabetes on carotid wall 18F-ﬂuorodeoxyglucose positron emis-
sion tomography uptake. J Am Coll Cardiol 2012;59:2080–8.
69. Gaemperli O, Shalhoub J, Owen DR, et al. Imaging intraplaque inﬂam-
mation in carotid atherosclerosis with 11C-PK11195 positron emission
tomography/computed tomography. Eur Heart J 2012;33:1902–10.
70. Dweck MR, Chow MW, Joshi NV, et al. Coronary arterial 18F-
sodium ﬂuoride uptake: a novel marker of plaque biology. J Am Coll
Cardiol 2012;59:1539–48.
71. Bucerius J, Manka C, Schmaljohann J, et al. Feasibility of [18F]-2-
Fluoro-A85380-PET imaging of human vascular nicotinic acetyl-
choline receptors in vivo. J Am Coll Cardiol Img 2012;5:528–36.
72. Wang X, Hagemeyer CE, Hohmann JD, et al. Novel single-chain
antibody-targeted microbubbles for molecular ultrasound imaging of
thrombosis: validation of a unique noninvasive method for rapid and
sensitive detection of thrombi and monitoring of success or failure of
thrombolysis in mice. Circulation 2012;125:3117–26.
73. Giannarelli C, Cimmino G, Connolly TM, et al. Synergistic effect of
liver X receptor activation and simvastatin on plaque regression and
stabilization: an magnetic resonance imaging study in a model of
advanced atherosclerosis. Eur Heart J 2012;33:264–73.
74. Vucic E, Calcagno C, Dickson SD, et al. Regression of inﬂammation
in atherosclerosis by the LXR agonist R211945: a noninvasive
assessment and comparison with atorvastatin. J Am Coll Cardiol Img
2012;5:819–28.75. Tan CE, Glantz SA. Association between smoke-free legislation and
hospitalizations for cardiac, cerebrovascular, and respiratory diseases:
a meta-analysis. Circulation 2012;126:2177–83.
76. Suzuki T, Kohro T, Hayashi D, Yamazaki T, Nagai R. Frequency and
impact of lifestyle modiﬁcation in patients with coronary artery
disease: the Japanese Coronary Artery Disease (JCAD) study. Am
Heart J 2012;163:268–73.
77. Dehghan M, Mente A, Teo KK, et al. Relationship between healthy
diet and risk of cardiovascular disease among patients on drug therapies
for secondary prevention: a prospective cohort study of 31 546 high-
risk individuals from 40 countries. Circulation 2012;126:2705–12.
78. Estruch R, Ros E, Salas-Salvado J, et al. Primary prevention of
cardiovascular disease with a Mediterranean diet. N Engl J Med 2013;
368:1279–90.
79. Sjostrom L, Peltonen M, Jacobson P, et al. Bariatric surgery and long-
term cardiovascular events. JAMA 2012;307:56–65.
80. Naderi SH, Bestwick JP, Wald DS. Adherence to drugs that prevent
cardiovascular disease: meta-analysis on 376,162 patients. Am J Med
2012;125:882–887.e1.
81. Farkouh ME, Boden WE, Bittner V, et al. Risk factor control for
coronary artery disease secondary prevention in large randomized
trials. J Am Coll Cardiol 2013;61:1607–15.
82. Savarese G, Costanzo P, Cleland JG, et al. A meta-analysis reporting
effects of angiotensin-converting enzyme inhibitors and angiotensin
receptor blockers in patients without heart failure. J Am Coll Cardiol
2012;61:131–42.
83. McAlister FA. Angiotensin-converting enzyme inhibitors or angio-
tensin receptor blockers are beneﬁcial in normotensive atherosclerotic
patients: a collaborative meta-analysis of randomized trials. Eur Heart
J 2012;33:505–14.
84. McBrien K, Rabi DM, Campbell N, et al. Intensive and standard blood
pressure targets in patients with type 2 diabetes mellitus: systematic
review and meta-analysis. Arch Intern Med 2012;172:1296–303.
85. Redon J, Mancia G, Sleight P, et al. Safety and efﬁcacy of low blood
pressures among patients with diabetes: subgroup analyses from the
ONTARGET (ONgoing Telmisartan Alone and in combination with
Ramipril Global Endpoint Trial). J Am Coll Cardiol 2012;59:74–83.
86. Gerstein HC, Bosch J, Dagenais GR, et al. Basal insulin and
cardiovascular and other outcomes in dysglycemia. N Engl J Med
2012;367:319–28.
87. Bosch J, Gerstein HC, Dagenais GR, et al. n-3 fatty acids and
cardiovascular outcomes in patients with dysglycemia. N Engl J Med
2012;367:309–18.
88. Rizos EC, Ntzani EE, Bika E, Kostapanos MS, Elisaf MS. Associ-
ation between omega-3 fatty acid supplementation and risk of major
cardiovascular disease events: a systematic review and meta-analysis.
JAMA 2012;308:1024–33.
89. Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Low-dose
colchicine for secondary prevention of cardiovascular disease. J Am
Coll Cardiol 2012;61:404–10.
90. Mihaylova B, Emberson J, Blackwell L, et al. The effects of lowering
LDL cholesterol with statin therapy in people at low risk of vascular
disease: meta-analysis of individual data from 27 randomised trials.
Lancet 2012;380:581–90.
91. Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardio-
vascular beneﬁts and diabetes risks of statin therapy in primary preven-
tion: an analysis from the JUPITER trial. Lancet 2012;380:565–71.
92. Waters DD, Ho JE, Boekholdt SM, et al. Cardiovascular event
reduction versus new-onset diabetes during atorvastatin therapy: effect
of baseline risk factors for diabetes. J Am Coll Cardiol 2012;61:148–52.
93. Giugliano RP, Desai NR, Kohli P, et al. Efﬁcacy, safety, and toler-
ability of a monoclonal antibody to proprotein convertase subtilisin/
kexin type 9 in combination with a statin in patients with hyper-
cholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-
controlled, dose-ranging, phase 2 study. Lancet 2012;380:2007–17.
94. Koren MJ, Scott R, Kim JB, et al. Efﬁcacy, safety, and tolerability of
a monoclonal antibody to proprotein convertase subtilisin/kexin type 9
as monotherapy in patients with hypercholesterolaemia (MENDEL):
a randomised, double-blind, placebo-controlled, phase 2 study. Lancet
2012;380:1995–2006.
95. McKenney JM, Koren MJ, Kereiakes DJ, Hanotin C, Ferrand AC,
Stein EA. Safety and efﬁcacy of a monoclonal antibody to proprotein
convertase subtilisin/kexin type 9 serine protease, SAR236553/
JACC Vol. 62, No. 13, 2013 Sanz et al.
September 24, 2013:1131–1143 The Year in Atherothrombosis
1143REGN727, in patients with primary hypercholesterolemia receiving
ongoing stable atorvastatin therapy. J Am Coll Cardiol 2012;59:2344–53.
96. Ibanez B, Giannarelli C, Cimmino G, et al. Recombinant
HDL(Milano) exerts greater anti-inﬂammatory and plaque stabilizing
properties than HDL(wild-type). Atherosclerosis 2012;220:72–7.
97. Lavigne PM, Karas RH. The current state of niacin in cardiovascular
disease prevention: a systematic review and meta-regression. J Am
Coll Cardiol 2013;61:440–6.
98. Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in
patients with a recent acute coronary syndrome. N Engl J Med 2012;
367:2089–99.
99. Luscher TF, Taddei S, Kaski JC, et al. Vascular effects and safety of
dalcetrapib in patients with or at risk of coronary heart disease: the
dal-VESSEL randomized clinical trial. Eur Heart J 2012;33:857–65.
100. Charlot M, Nielsen LH, Lindhardsen J, et al. Clopidogrel discon-
tinuation after myocardial infarction and risk of thrombosis:
a nationwide cohort study. Eur Heart J 2012;33:2527–34.
101. Kim BK,HongMK, Shin DH, et al. A new strategy for discontinuation
of dual antiplatelet therapy: the RESET Trial (REal Safety and Efﬁcacy
of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-
eluting stent implantation). J Am Coll Cardiol 2012;60:1340–8.
102. Ferreira-Gonzalez I, Marsal JR, Ribera A, et al. Double antiplatelet
therapy after drug-eluting stent implantation: risk associated with
discontinuation within the ﬁrst year. J Am Coll Cardiol 2012;60:1333–9.
103. Dewilde WJ, Oirbans T, Verheugt FW, et al. Use of clopidogrel with
or without aspirin in patients taking oral anticoagulant therapy and
undergoing percutaneous coronary intervention: an open-label, rand-
omised, controlled trial. Lancet 2013;381:1107–15.
104. Roe MT, Armstrong PW, Fox KA, et al. Prasugrel versus clopidogrel
for acute coronary syndromes without revascularization. N Engl J Med
2012;367:1297–309.
105. Morrow DA, Braunwald E, Bonaca MP, et al. Vorapaxar in the
secondary prevention of atherothrombotic events. N Engl J Med
2012;366:1404–13.
106. Scirica BM, Bonaca MP, Braunwald E, et al. Vorapaxar for secondary
prevention of thrombotic events for patients with previous myocardial
infarction: a prespeciﬁed subgroup analysis of the TRA 2 degrees P-
TIMI 50 trial. Lancet 2012;380:1317–24.
107. Gurbel PA, Erlinge D, Ohman EM, et al. Platelet function during
extended prasugrel and clopidogrel therapy for patients with ACS
treated without revascularization: the TRILOGY ACS platelet
function substudy. JAMA 2012;308:1785–94.
108. Collet JP, Cuisset T, Range G, et al. Bedside monitoring to adjust
antiplatelet therapy for coronary stenting. N Engl J Med 2012;367:
2100–9.109. Trenk D, Stone GW, Gawaz M, et al. A randomized trial of prasugrel
versus clopidogrel in patients with high platelet reactivity on clopi-
dogrel after elective percutaneous coronary intervention with
implantation of drug-eluting stents: results of the TRIGGER-PCI
(Testing Platelet Reactivity In Patients Undergoing Elective Stent
Placement on Clopidogrel to Guide Alternative Therapy With Pra-
sugrel) study. J Am Coll Cardiol 2012;59:2159–64.
110. Reny JL, Berdague P, Poncet A, et al. Antiplatelet drug response
status does not predict recurrent ischemic events in stable cardiovas-
cular patients: results of the Antiplatelet Drug Resistances and
Ischemic Events study. Circulation 2012;125:3201–10.
111. De Bruyne B, Pijls NH, Kalesan B, et al. Fractional ﬂow reserve-
guided PCI versus medical therapy in stable coronary disease.
N Engl J Med 2012;367:991–1001.
112. Mohr FW, Morice MC, Kappetein AP, et al. Coronary artery bypass
graft surgery versus percutaneous coronary intervention in patients with
three-vessel disease and left main coronary disease: 5-year follow-up of
the randomised, clinical SYNTAX trial. Lancet 2013;381:629–38.
113. Farooq V, van Klaveren D, Steyerberg EW, et al. Anatomical and
clinical characteristics to guide decision making between coronary
artery bypass surgery and percutaneous coronary intervention for
individual patients: development and validation of SYNTAX score II.
Lancet 2013;381:639–50.
114. Brooks MM, Chaitman BR, Nesto RW, et al. Clinical and angio-
graphic risk stratiﬁcation and differential impact on treatment
outcomes in the Bypass Angioplasty Revascularization Investigation 2
Diabetes (BARI 2D) trial. Circulation 2012;126:2115–24.
115. Farkouh ME, Domanski M, Sleeper LA, et al. Strategies for multi-
vessel revascularization in patients with diabetes. N Engl J Med 2012;
367:2375–84.
116. Magnuson EA, Farkouh ME, Fuster V, et al. Cost-effectiveness of
percutaneous coronary intervention with drug eluting stents versus
bypass surgery for patients with diabetes and multivessel coronary
artery disease: results from the FREEDOM Trial. Circulation 2013;
127:820–31.Key Words: atherosclerosis - imaging - risk factors - thrombosis -
vasculature.
APPENDIX
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